Anumana’s AI algorithm for cardiac amyloidosis gets FDA breakthrough nod
Related Articles
Fierce Medtech’s 2022 Fierce 15
Fierce Medtech: Since its humble beginnings back in 2012, the Fierce 15 has made a point of spotlighting the most exciting startups in medtech—those not only challenging the limits of…{post_date: F d, Y}
Trial demonstrates early AI-guided detection of heart disease in routine practice
Medical Xpress: Heart disease can take a number of forms, but some types of heart disease, such as asymptomatic low ejection fraction, can be hard to recognize, especially in the…{post_date: F d, Y}
Anumana to Share Latest Advances in ECG-AI at AHA Scientific Sessions 2025
Company to present four studies, including a late-breaking featured science presentation, and host interactive experiences demonstrating AI’s role in cardiovascular care{post_date: F d, Y}
Anumana Makes Educated Inferences in Heart Failure
Anumana was founded in 2021 as the culmination of a joint effort between the Mayo Clinic and nference, an early entrant to the field of machine learning for cardiology-focused clinical…{post_date: F d, Y}